[{"id":"06f2e6a8-bdd2-4a87-bef8-65924c69c48b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04855253","created_at":"2021-04-22T20:53:39.288Z","updated_at":"2024-07-02T16:35:43.683Z","phase":"Phase 1/2","brief_title":"Study of E7777 Prior to Kymriah for R/R DLBCL","source_id_and_acronym":"NCT04855253","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" MYC","pipe":" | ","alterations":" MYC expression","tags":["MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T) • Ontak (denileukin diftitox) • Lymphir (denileukin diftitox-cxdl)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/09/2021","start_date":" 06/09/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-07-07"},{"id":"2206fad9-2403-4d16-b774-a54c873db7db","acronym":"","url":"https://clinicaltrials.gov/study/NCT01871727","created_at":"2021-01-18T08:23:02.004Z","updated_at":"2024-07-02T16:35:59.275Z","phase":"Phase 3","brief_title":"A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma","source_id_and_acronym":"NCT01871727","lead_sponsor":"Eisai Inc.","biomarkers":" IL2RA • IL2 • ISG20","pipe":"","alterations":" ","tags":["IL2RA • IL2 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ontak (denileukin diftitox) • Lymphir (denileukin diftitox-cxdl)"],"overall_status":"Completed","enrollment":" Enrollment 112","initiation":"Initiation: 05/30/2013","start_date":" 05/30/2013","primary_txt":" Primary completion: 12/06/2021","primary_completion_date":" 12/06/2021","study_txt":" Completion: 12/14/2021","study_completion_date":" 12/14/2021","last_update_posted":"2022-12-12"},{"id":"31adcbe2-0d5d-4ada-8822-41d45bc4d363","acronym":"","url":"https://clinicaltrials.gov/study/NCT01127451","created_at":"2021-01-18T04:28:36.703Z","updated_at":"2024-07-02T16:36:12.815Z","phase":"Phase 2","brief_title":"Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma","source_id_and_acronym":"NCT01127451","lead_sponsor":"Eisai Inc.","biomarkers":" BRAF • CTLA4 • CD4 • IL7R • ISG20","pipe":"","alterations":" ","tags":["BRAF • CTLA4 • CD4 • IL7R • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ontak (denileukin diftitox)"],"overall_status":"Completed","enrollment":" Enrollment 75","initiation":"Initiation: 06/22/2010","start_date":" 06/22/2010","primary_txt":" Primary completion: 04/07/2015","primary_completion_date":" 04/07/2015","study_txt":" Completion: 04/07/2015","study_completion_date":" 04/07/2015","last_update_posted":"2022-04-13"},{"id":"5b6436a7-560a-4215-a007-3fdd787d2b36","acronym":"","url":"https://clinicaltrials.gov/study/NCT02676778","created_at":"2021-07-15T17:53:07.245Z","updated_at":"2024-07-02T16:36:27.892Z","phase":"Phase 2","brief_title":"Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma","source_id_and_acronym":"NCT02676778","lead_sponsor":"Eisai Co., Ltd.","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ontak (denileukin diftitox) • Lymphir (denileukin diftitox-cxdl)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 03/28/2016","start_date":" 03/28/2016","primary_txt":" Primary completion: 04/26/2019","primary_completion_date":" 04/26/2019","study_txt":" Completion: 04/26/2019","study_completion_date":" 04/26/2019","last_update_posted":"2021-07-15"},{"id":"5863acfa-2c73-4457-b4d3-80c62547746a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00211185","created_at":"2021-01-18T00:43:02.645Z","updated_at":"2024-07-02T16:36:48.256Z","phase":"Phase 2","brief_title":"A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma","source_id_and_acronym":"NCT00211185","lead_sponsor":"Eisai Inc.","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Ontak (denileukin diftitox) • Neulasta (pegfilgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 03/14/2004","start_date":" 03/14/2004","primary_txt":" Primary completion: 08/01/2008","primary_completion_date":" 08/01/2008","study_txt":" Completion: 12/23/2009","study_completion_date":" 12/23/2009","last_update_posted":"2020-03-18"},{"id":"b86a46ce-9239-437b-8205-8587adbd65e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00357448","created_at":"2021-01-18T01:14:18.217Z","updated_at":"2024-07-02T16:36:59.620Z","phase":"Phase 1","brief_title":"Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer","source_id_and_acronym":"NCT00357448","lead_sponsor":"University of Washington","biomarkers":" IL6 • TNFA • IL2 • IL10 • TGFB1 • TGFB2","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL2 • IL10 • TGFB1 • TGFB2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ontak (denileukin diftitox)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 04/01/2005","start_date":" 04/01/2005","primary_txt":" Primary completion: 11/01/2009","primary_completion_date":" 11/01/2009","study_txt":"","study_completion_date":"","last_update_posted":"2019-05-14"},{"id":"3b7aa45c-07ba-4421-ad73-bd3b53ea28b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00425672","created_at":"2021-01-18T01:29:59.629Z","updated_at":"2024-07-02T16:37:04.882Z","phase":"Phase 1/2","brief_title":"ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment","source_id_and_acronym":"NCT00425672","lead_sponsor":"University of Washington","biomarkers":" IL2RA","pipe":" | ","alterations":" IL2RA expression • IL2 expression","tags":["IL2RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA expression • IL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ontak (denileukin diftitox)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 09/01/2005","start_date":" 09/01/2005","primary_txt":" Primary completion: 04/01/2010","primary_completion_date":" 04/01/2010","study_txt":"","study_completion_date":"","last_update_posted":"2018-12-05"},{"id":"16b0da6f-245d-47b0-a45e-00b6509e57da","acronym":"","url":"https://clinicaltrials.gov/study/NCT00460109","created_at":"2021-01-18T01:38:02.217Z","updated_at":"2024-07-02T16:37:23.304Z","phase":"Phase 2","brief_title":"Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00460109","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" ALB","pipe":"","alterations":" ","tags":["ALB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Ontak (denileukin diftitox)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 04/01/2008","start_date":" 04/01/2008","primary_txt":" Primary completion: 10/01/2010","primary_completion_date":" 10/01/2010","study_txt":" Completion: 03/01/2011","study_completion_date":" 03/01/2011","last_update_posted":"2017-04-18"},{"id":"dffc2e2b-2f17-4a8f-90f8-d3b57d6cd21a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00082940","created_at":"2021-01-18T00:14:06.839Z","updated_at":"2024-07-02T16:37:26.399Z","phase":"Phase 2","brief_title":"Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT00082940","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" CD5","pipe":"","alterations":" ","tags":["CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • Ontak (denileukin diftitox)"],"overall_status":"Completed","enrollment":"","initiation":"Initiation: 08/01/2002","start_date":" 08/01/2002","primary_txt":" Primary completion: 01/01/2005","primary_completion_date":" 01/01/2005","study_txt":" Completion: 06/01/2005","study_completion_date":" 06/01/2005","last_update_posted":"2017-01-19"},{"id":"c4090cb9-14c2-4c40-bba0-1b390a98222c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00513188","created_at":"2021-01-18T01:50:50.941Z","updated_at":"2024-07-02T16:37:27.039Z","phase":"","brief_title":"Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT00513188","lead_sponsor":"University of Miami","biomarkers":" IL2RA • ISG20","pipe":" | ","alterations":" IL2RA expression","tags":["IL2RA • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • leucovorin calcium • Ontak (denileukin diftitox)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2007","start_date":" 02/01/2007","primary_txt":" Primary completion: 06/01/2008","primary_completion_date":" 06/01/2008","study_txt":"","study_completion_date":"","last_update_posted":"2016-12-15"}]